Read More

Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly

Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart disease, heart attack, and stroke.

LLY